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Abstract

Comparative effectiveness evidence from randomized trials may not be directly generalizable to a target
population of substantive interest when, as in most cases, trial participants are not randomly sampled
from the target population. Motivated by the need to generalize evidence from two trials conducted in the
AIDS Clinical Trials Group (ACTG), we consider weighting, regression and doubly robust estimators
to estimate the causal effects of HIV interventions in a specified population of people living with HIV
in the USA. We focus on a non-nested trial design and discuss strategies for both point and variance
estimation of the target population average treatment effect. Specifically in the generalizability context,
we demonstrate both analytically and empirically that estimating the known propensity score in trials
does not increase the variance for each of the weighting, regression and doubly robust estimators. We
apply these methods to generalize the average treatment effects from two ACTG trials to specified target
populations and operationalize key practical considerations. Finally, we report on a simulation study
that investigates the finite-sample operating characteristics of the generalizability estimators and their
sandwich variance estimators.
K EY WORDS: Causal inference; double robustness; internal validity; inverse probability weighting;
generalizability; propensity score; sampling score
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1.1

Introduction
The AIDS Clinical Trials Group Studies

The AIDS Clinical Trials Group (ACTG) is the largest research network conducting randomized trials
to study the safety and efficacy of interventions for individuals infected with human immunodeficiency
virus (HIV) and those who develop acquired immunodeficiency syndrome (AIDS) (Green et al., 1990).
Our motivating applications include two ACTG trials—ACTG 320 and ACTG A5202—that evaluated
the efficacy of antiretroviral therapy among individuals infected with HIV. ACTG 320 compared a threedrug treatment regimen where a protease inhibitor (PI) was added to zidovudine and lamivudine with
a treatment regimen only including the two nucleoside analogues, and found that adding PI significantly slowed disease progression (Hammer et al., 1997). ACTG A5202 assessed the equivalence
of abacavir-lamivudine (ABC-3TC) and tenofovir disoproxil fumarate-emtricitabine (TDF-FTC), and
found that treatment with TDF-FTC was associated with lower risk of virologic failure among patients
with baseline viral load > 100, 000 copies/ml (Sax et al., 2009, 2011). Because randomization balances
both measured and unmeasured baseline confounders in expectation, the sample average treatment effect (SATE) represents a valid comparative parameter among the trial population (Greenland, 1990).
However, generalizability of trial results to a broader target population living with HIV without careful
considerations can be questionable because the trial population often has a different distribution of effect
modifiers compared to the target population (Gandhi et al., 2005).
We investigate whether the results of ACTG 320 and ACTG A5202 are generalizable to two target
populations: all people living with HIV in the USA, and all women living with HIV in the USA. We
estimate the population average treatment effect (PATE) in terms of the change in CD4 cell counts from
baseline, in the absence of information on such outcomes from these target populations. Specifically,
we combine the data on baseline covariates, treatments, and the outcome from the trials with baseline
covariates from two cohort studies: the Center for AIDS Research Network of Integrated Clinical Systems (CNICS) (Kitahata et al., 2008) and the Women’s Interagency HIV Study (WIHS) (Adimora et al.,
2018). For our purposes, we assume members of CNICS and WIHS are representative of all people
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living with HIV in the USA and all women living with HIV in the USA, respectively (Bacon et al.,
2005). Compared to the CNICS and WIHS cohorts, African-American and Hispanic women, as well as
patients over 40 years were relatively under-represented in both ACTG trials (Buchanan et al., 2018).
Because race and age may be strong effect modifiers (Greenbaum et al., 2008; Ribaudo et al., 2013),
the average treatment effects in trial population may be different from those in the target populations.
Therefore, generalizing comparative results from the trials to the target populations requires adjusting
for the differential distributions of effect modifiers between the trials and the target populations (Kern
et al., 2016).

1.2

Related Literature on Generalizability

Typical approaches for generalizing trial results include subclassification (Tipton, 2013; O’Muircheartaigh
and Hedges, 2013), outcome regression (Wang and Rosner, 2019), and inverse probability weighting
(Cole and Stuart, 2010; Stuart et al., 2011; Hartman et al., 2015; Buchanan et al., 2018). These approaches often characterize the sampling mechanism through which patients are selected into the trials
or the cohorts. Following Buchanan et al. (2018), we call the probability of participation in the trial
conditional on a set of covariates explaining the sampling mechanism as the sampling score. Parallel
to the treatment propensity score which plays a central role in observational studies (Rosenbaum and
Rubin, 1983), the sampling score represents a key quantity conditional on which the trial and population
become exchangeable. In practice, the sampling score is often unknown but can be estimated. When the
sampling score model is correctly specified, Buchanan et al. (2018) demonstrated that inverse probability of sampling weighting (IPSW) outperformed subclassification, and provided a consistent sandwich
variance of the IPSW estimator. In our work, we will also investigate weighting-based estimators, but
do not further consider the subclassification estimators.
The IPSW generalization approach has been used in Stuart et al. (2011) to extend experimental
findings in nested trial designs, where the trial is assumed to be nested within the target population
and the baseline characteristics are fully observed in the target population. Our application concerns
a non-nested design where the trial sample and the sample from the target population are obtained
3

separately (Dahabreh and Hernan, 2018). In particular, we assume that the characteristics of the target
population are only ascertained within a random sample from the target population (the CNICS and
WIHS cohorts). Buchanan et al. (2018) proposed the IPSW approach to generalize trial results to the
target population from such a non-nested design. The consistency of the IPSW estimator, however,
depends on correct specification of the sampling score model. Further, it is also known that inverse
weighting by the sampling score alone may not be statistically efficient (Robins et al., 1994).
To improve IPSW, Dahabreh et al. (2018, 2020) considered doubly robust (DR) estimators for generalizability. Compared to IPSW, DR estimator additionally exploits the smoothness of outcome models,
and provides consistent estimates to PATE if either the sampling score or the outcome model is correctly
specified, but not necessarily both (Bang and Robins, 2005). Frequently, we do not know which model
is correct; thus, the DR estimator provides some degree of protection against model misspecification by
granting two chances for valid inference. Of note, Dahabreh et al. (2018) mainly focused on a nested
trial design, but the estimators derived for the nested design may not necessarily lead to consistent
estimates under the non-nested design. Li et al. (2021) and Lee et al. (2021) have both developed calibration weighting estimators for generalizability in the nested and non-nested designs. The calibration
weighting approach exploits the covariate-balancing constraints to achieve exact finite-sample balance
and double robustness asymptotically. Rudolph and van der Laan (2017) developed targeted maximum
likelihood estimators (TMLE) for transporting the intention-to-treat average effect, the average effect
due to the actual treatment, and the complier average treatment effect under a non-nested design with
patient noncompliance. Depending on the causal estimand, their estimator is doubly or multiply robust
and may require an additional model for the actual treatment received.
We provide a brief synthesis of the generalizability literature in Table 1 to further elucidate the
contribution of our article for non-nested designs. Our setting differs from Cole and Stuart (2010) and
Hartman et al. (2015) in that we observe the covariates of a large target population only through a smaller
random sample. Our setting closely resembles that in Buchanan et al. (2018). While Buchanan et al.
(2018) considered the IPSW estimator that only depends on the sampling score, we expand their work
to doubly robust estimation and explain the important role of the treatment propensity score for the pur4

pose of generalizability. Specifically, we demonstrate both analytically and empirically that estimating
the treatment propensity score can lead to notable efficiency gain for generalizing the SATE. Further,
different from Rudolph and van der Laan (2017) and Lee et al. (2021), we focus on parametric modeling of the nuisance parameters, and contribute a set of computationally convenient sandwich variance
estimators that account for the uncertainty in estimating the parametric models (with R code provided
in Web Appendix 5). The closed-form sandwich variances for the DR estimators, for example, have
not been explicitly derived in the generalizability literature. Finally, we also present a comprehensive
case study to assess the generalizability of two ACTG trials and operationalize key considerations for
estimating PATE and its corresponding sampling variance.
[Table 1 about here.]
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Notation and Assumptions

Suppose the scientific interest lies in drawing inference about the effect of a time-fixed binary treatment
on an outcome measured at the end of follow-up in a target population. We assume that each individual in
the target population has a pair of potential outcomes {Y 0 , Y 1 } (Rubin, 1978). Here Y 0 is the outcome
that would have been observed if, possibly contrary to fact, the individual received “usual care” (e.g., the
conventional treatment regimen with two nucleoside analogues in ACTG 320), and Y 1 is the outcome
that would have been seen if the individual received “treatment” (e.g., the treatment regimen that also
included the PI). Define µ1 = E(Y 1 ) and µ0 = E(Y 0 ) as the average potential outcomes in the target
population. The causal parameter of interest is the PATE, defined as
∆ = E(Y 1 − Y 0 ) = µ1 − µ0 .
To estimate ∆, we consider a scenario with two sources of available information: a sample of n individuals from the target population who participate in a trial (i.e., one of the ACTG trials), and a cohort
of m individuals (i.e., the CNICS or WIHS study) randomly drawn from the target population. While
the cohort is assumed to be representative of the target population, the trial participants often differ from
5

the non-randomized individuals in important ways. We further assume the knowledge of the size of
the actual population from which the cohort participants are sampled, which is sufficient for estimating
parameters in the sampling score model. We do not require that the trial participants are nested in the
cohort sample; this is a practical consideration because individual identifiers are frequently unavailable.
Throughout we make the Stable Unit Treatment Value Assumption (SUTVA), which implies treatment variation irrelevance and no interference. The assumption of treatment variation irrelevance holds
if the same version of treatment could be provided to all trial participants and (potentially) non-participants
in the target population, or if differences among versions of treatment (such as delivery mechanism) are
irrelevant to the outcome of interest (VanderWeele, 2009). This assumption may be invalid, for example, when the treatment administration in the trial is accompanied by adherence counseling, while
such counseling is absent when treatment is provided to the non-randomized participants. The absence
of interference means that the potential outcome of each individual does not depend on the treatment
received by others (Hudgens and Halloran, 2008). This assumption may be questionable, for example,
in a vaccine trial, where the vaccination status of one individual may affect whether another individual
develops flu due to herd immunity.
Let Z be a p-vector of baseline covariates observed for both the trial and cohort participants. Define
S = 1 if the individual participates in the trial and S = 0 otherwise. For trial participants, define X as
the treatment indicator, with X = 1 indicating active treatment and X = 0 otherwise. Under SUTVA,
the observed outcome for each trial participant is Y = Y 1 X + Y 0 (1 − X), while we do not observe
either treatment or outcome within the cohort. We also define D as an indicator for inclusion in the
study, where D = 1 implies the individual is included in the observed data (combined trial or cohort
sample) and D = 0 otherwise. Furthermore, we assume that if S = 1, then D = 1. In short, we observe
information on (Z, S = 1, X, Y, D = 1) for trial participants, and information on (Z, S = 0, D = 1)
for the cohort sample. Notice that our set up differs from Wang and Rosner (2019) in that we assume
neither Y nor X are observed in the cohort study (CNICS or WIHS). In cases when both Y and X are
available in multiple cohort studies, we refer to Wang and Rosner (2019) who developed a Bayesian
nonparametric outcome regression estimator for integrative analysis of trials and cohorts. In our setting,
6

as we do not observe all potential outcomes in the target population, the identification and inference for
∆ requires the following two assumptions.
A SSUMPTION 1 (Randomization) The treatment is randomly assigned in the trial, namely
P(X = 1|S = 1, Z, Y 0 , Y 1 ) = P(X = 1|S = 1).

(2.1)

The randomization probability P(X = 1|S = 1) = r ∈ (0, 1).
A SSUMPTION 2 (Ignorable Trial Participation) Conditional on the set of covariates Z, trial participation is independent of the potential outcomes, namely,
P(S = 1|Z, Y 0 , Y 1 ) = P(S = 1|Z).

(2.2)

The sampling score, defined as w(Z) = P(S = 1|Z), is strictly positive for all Z with a positive density.
Typically, the treatment is randomly assigned in the trial and Assumption 1 holds by design. In
this case, the true treatment propensity score is e(W ) = P(X = 1|S = 1, W ) = r, for any subset
of baseline covariates W ⊆ Z. Assumption 2 requires exchangeability between trial participants and
non-participants conditional on the pre-treatment covariates Z. Assumption 2 further requires positivity
in trial participation such that there is a positive probability of participating in the trial for each value
of the covariates (Westreich and Cole, 2010). Although positivity can be checked by visualizing the
distribution of the estimated sampling scores (Stuart et al., 2011), the conditional exchangeability (2.2)
is not testable and merits sensitivity analysis (Nguyen et al., 2017). Finally, we assume the absence of
noncompliance such that the treatment actually received by each individual is the same as the randomized treatment within the trial. In the presence of treatment noncompliance, there exist alternative causal
estimands to describe the within-trial treatment effect, including the per-protocol causal effect and the
complier average causal effect. Additional structural assumptions and different statistical strategies are
required to enable identification of these alternative within-trial causal estimands, prior to generalizations to new target populations. We refer to Rudolph and van der Laan (2017) and Lu et al. (2019)
for more explicit definitions of alternative estimands and generalization strategies in the presence of
noncompliance.
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3
3.1

Estimating Population Average Treatment Effect
Preliminaries

We consider five estimators of ∆ to generalize trial results to a specified target population. We assume a finite-dimensional logistic model for the sampling scores w(Z; γ) = P(S = 1|Z; γ) = {1 +
exp(−Z T γ)}−1 , where γ is a p-vector of regression coefficients. Throughout we assume the vector Z
includes 1 as the first component to accommodate an intercept. Let γ
b denote the weighted maximum
likelihood estimator of γ where each trial participant is given weight Π−1
1 = 1 and each member in the
cohort is given weight Π−1
0 = (N − n)/m, and N is the target population size (Scott and Wild, 1986).
−1
−1
Because the weight depends only on trial participation status, we write Π−1
Si = Si Π1 + (1 − Si )Π0 . In

our setting, the trial sample is much smaller than the target population, and we could reasonably approximate the inclusion probability π0 = P(D = 1|S = 0) ≈ m/(N − n), which motivates the choice of
weight Π0−1 . The intuition behind Π−1
0 is that it replaces each cohort participant by (N − m)/m copies
of him or herself to fully represent the N − m non-randomized participants in the target population,
so that all N observations in the target population are used to estimate w(Z) without conditioning on
D = 1. On the other hand, if the cohort sample coincides with the target population, then m = N and
Π−1
0 = (m − n)/m ≈ 1 and our estimators approximate those developed for the nested trial design
(Stuart et al., 2011; Dahabreh et al., 2018). For each observation in the trial and the cohort, we denote
the estimated sampling score by w
bi = w(Zi ; γ
b).
Although the true treatment propensity score is known in the trials, estimating the propensity score
(rather than the using the true value) may lead to improved efficiency of the SATE estimator, by controlling for chance imbalance (Rosenbaum, 1987; Hirano et al., 2003). For a set of baseline covariates W ⊆ Z, we use a working logistic model for the propensity scores e(W ; β) = P(X = 1|S =
1, W ; β) = {1 + exp(−W T β)}−1 , where β is a q-vector of coefficients. Specifically, one could include
prognostic covariates or covariates that exhibit baseline imbalance into W . In this case, we write βb as
b Dahabreh et al.
the maximum likelihood estimator, and the estimated propensity scores ebi = e(Wi ; β).
(2018) recommended using the estimated propensity scores in nested trial designs, but did not provide
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an mathematical justification. To strengthen that recommendation, we establish asymptotic results in
Section 4.3 and show that the potential efficiency gain due to estimating propensity scores applies to all
five generalizability estimators we consider below.

3.2

Inverse Probability of Sampling Weighting

We first consider two IPSW estimators; both estimators weight the trial sample by the inverse of the estimated sampling score to approximate the covariate distribution in the target population. If the sampling
score model is correctly specified, both estimators remove the bias due to non-random trial participation
and provide consistent estimates of PATE. With the estimated sampling scores and treatment propensity
scores, the first IPSW estimator is akin to a Horvitz-Thompson estimator in survey sampling, and is
written as
N
N
X
Di Si Xi Yi
1 X Di Si (1 − Xi )Yi
b IPSW1 = 1
∆
−
.
N
w
bi ebi
N
w
bi (1 − ebi )
i=1

(3.1)

i=1

The second IPSW estimator is akin to the Hájek estimator, and is given by
PN
b IPSW2 =
∆

Di Si Xi Yi /w
bi ebi
Pi=1
N
bi ebi
i=1 Di Si Xi /w

PN

− Pi=1
N

Di Si (1 − Xi )Yi /w
bi (1 − ebi )

i=1 Di Si (1

− Xi )/w
bi (1 − ebi )

.

(3.2)

b IPSW2 typically produces an effect estimate within the range of the
In the causal inference literature, ∆
b IPSW1 . Because P(D = 1|S = 1) = 1, the
observed outcomes and may be more efficient than ∆
b IPSW1 and ∆
b IPSW2 . We include Di in our presentation
inclusion indicator Di can be omitted from ∆
throughout because, as will be seen in Section 4, this notation allows us to treat the collection of all random variables as independent and identically distributed (IID) copies from the target population of size
b IPSW1 and ∆
b IPSW2 use an
N , allowing us to invoke the standard asymptotic theory for IID data. Both ∆
estimated treatment propensity score ebi . When the true treatment propensity score is used, however, the
propensity score factors out of the IPSW2 estimator, and we obtain the estimator studied by Buchanan
et al. (2018). We denote the corresponding estimators obtained by replacing ebi with the true propensity
e IPSW1 and ∆
e IPSW2 .
score as ∆
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3.3

Outcome Regression

For the outcome regression estimator, we write mx (Z) = E(Y x |Z, S = 1) for the conditional expectation of the potential outcome among trial participants under intervention x. By SUTVA, mx (Z) =
E(Y |Z, X = x, S = 1), and we could posit parametric models for these conditional expectations
mx (Z; αx ), x = 0, 1, where α1 and α0 are l1 × 1 and l0 × 1 vectors of regression coefficients, respectively. In general, we could obtain maximum likelihood estimators, α
e1 and α
e0 , as solutions to the
following estimating equations
N
X
i=1
N
X

Di Si Xi ψα1 (Yi , Zi ; α1 ) = 0

(3.3)

Di Si (1 − Xi )ψα0 (Yi , Zi ; α0 ) = 0

(3.4)

i=1

where ψα1 (Yi , Zi ; α1 ) and ψα0 (Yi , Zi ; α0 ) are score functions determined by model specification. For
example, if we use a linear model m1 (Z) = Z T α1 , then ψα1 (Yi , Zi ; α1 ) = Zi (Yi − ZiT α1 ). Notice that equations (3.3) and (3.4) correspond to a strategy that fits a separate regression model within
each treatment group. In the presence of treatment-by-covariate interactions, this strategy obviates the
need to estimate treatment-by-covariate interactions, but is identical to fitting a single regression model
in the trial sample including full treatment-by-covariate interactions (Lunceford and Davidian, 2004;
Dahabreh et al., 2020). We write the predicted outcome for each individual as m
e 1i = m1 (Zi ; α
e1 ),
m
e 0i = m0 (Zi ; α
e0 ), and define the outcome regression (REG) estimator of the PATE as
N
1 X
e
ci (m
e 1i − m
e 0i ).
∆REG =
N

(3.5)

i=1

where ci = Di {Si + Π−1
0 (1 − Si )} is a population standardization factor that depends on the inclusion
probability. Intuitively, because the cohort sample only includes m observations, the factor Π−1
0 replaces
each cohort participant by (N − m)/m copies of him or herself to fully represent the N − m none REG is
randomized participants in the target population. By this intuition, we could also see that ∆
consistent for ∆ when the outcome models are correctly specified.
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Alternatively, we consider an outcome analysis assisted by the estimated propensity scores. To do
that, we obtain α
b1 and α
b0 from the observed data by solving the following weighted estimating equations
N
X
i=1
N
X

ei = 0,
Di Si Xi ψα1 (Yi , Zi ; α1 )/b

(3.6)

Di Si (1 − Xi )ψα0 (Yi , Zi ; α0 )/(1 − ebi ) = 0.

(3.7)

i=1

Because the true propensity score is known by design, ebi is always correctly specified and estimating
equations (3.6) and (3.7) are unbiased as long as (3.3) and (3.4) are unbiased. Now write the predicted
outcome for each individual as m
b 1i = m1 (Zi ; α
b1 ), m
b 0i = m0 (Zi ; α
b0 ), the REG estimator becomes
N
X
b REG = 1
∆
ci (m
b 1i − m
b 0i ).
N

(3.8)

i=1

In particular, the above REG estimator differs from the standard REG estimator (3.5) as we have introduced inverse probability of treatment weighting. In fact, ebi is not required for the consistency of the
e REG as the version of (3.8) where the estimated propensity score is
REG estimator, and we can treat ∆
replaced by the truth ei = r. In this case, as the randomization probability is constant, the propensity
score term factors out of the estimating equations (3.6) and (3.7). From this perspective, ebi seems redundant for performing outcome regression. However, as we explain in Section 4.3, the use of ebi does
b REG is at least as efficient as ∆
e REG .
not increase the asymptotic variance; in other words, ∆

3.4

Doubly Robust Estimators

We additionally consider two DR estimators that combine IPSW and regression. Based on Assumptions
1 and 2, we show in Web Appendix 1 that the efficient influence function for estimating the PATE in our
non-nested design is
Ieff (Di , Si , Xi , Yi , Zi ) =

Di Si Xi
Di Si (1 − Xi )
(Yi − m1 (Zi )) −
(Yi − m0 (Zi ))
wi e i
wi (1 − ei )
+ Di {Si + π0−1 (1 − Si )}(m1 (Zi ) − m0 (Zi ) − ∆),

(3.9)

where wi , ei are the true sampling score and the propensity score, and the population standardization factor, Di {Si + π0−1 (1 − Si )}, depends on the true inclusion probability π0 . Replacing wi , ei
11

with estimated w
bi , ebi , and m1 (Zi ), m0 (Zi ) with the estimated m
b 1i , m
b 0i , the solution of ∆ based on
PN
i=1 Ieff (Di , Si , Xi , Yi , Zi ) = 0 motivates the first DR estimator

N 
1 X Di Si Xi
Di Si (1 − Xi )
b
∆DR1 =
(Yi − m
b 1i ) −
(Yi − m
b 0i ) + ci (m
b 1i − m
b 0i ) ,
(3.10)
N
w
bi ebi
w
bi (1 − ebi )
i=1

where ci = Di {Si + Π−1
0 (1 − Si )} is a population standardization factor that depends on the estimated
b DR1 is an IPSW1 estimator augmented by outcome regresinclusion probability Π0 . By construction, ∆
b IPSW1 , the inverse probability of sampling weights in ∆
b DR1 is unbounded and therefore
sion. Similar to ∆
motivates the application of Hájek weights to construct the second DR estimator,
PN
PN
b 1i )/w
bi ebi
Di Si (1 − Xi )(Yi − m
b 0i )/w
bi (1 − ebi )
i=1 Di Si Xi (Yi − m
b
∆DR2 =
− i=1PN
PN
bi ebi
bi (1 − ebi )
i=1 Di Si Xi /w
i=1 Di Si (1 − Xi )/w
+

N
1 X
ci (m
b 1i − m
b 0i ).
N

(3.11)

i=1

b DR1 and ∆
b DR2 use the estimated propensity score ebi , but we can again replace that with
The estimators ∆
e DR1 and ∆
e DR2 . Because
the known propensity score ei = r and define the corresponding estimators ∆
e DR2 .
the true propensity score is a constant, this term also factors out of ∆
b DR1 and ∆
b DR2 converge to
In Web Appendix 2, we confirm that, in our non-nested design, both ∆
∆ in large samples, as long as either the sampling score model or the outcome models are correctly
specified but not necessarily both. This property provides two opportunities for valid generalizability
analyses, and renders the DR estimators potentially more attractive over IPSW and REG alone. When
all models are correctly specified, the DR estimators are also more efficient than IPSW alone (Robins
et al., 1994). Of note, in a nested trial design where m = N , we have Π−1
0 ≈ 1 for the cohort sample and
b DR1 and ∆
b DR2 reduce to the DR estimators in Dahabreh et al. (2018). Finally, the robustness
therefore ∆
b DR1 and ∆
b DR2 suggests a practical approach to diagnose model misspecification (Robins
property of ∆
and Rotnitzky, 2001; Mercatanti and Li, 2014). That is, assuming visual assessment of the sampling
score distribution suggests no violation of positivity in trial participation, if DR estimate is different
from the REG estimate, but is close to IPSW estimate, it suggests potentially misspecified outcome
models. On the other hand, if the DR estimate is close to REG estimate but is different from IPSW, then
the model for the probability of trial participation may be misspecified.
12

4

Large-Sample Properties and Efficiency Considerations

We express each generalizability estimator as the solution to unbiased estimating equations to establish the consistency and asymptotic normality in the non-nested design setting. We focus on DR2, and
considerations for other estimators are given in Web Appendix 3. The unbiased estimating equations
representation permits the derivation of a sandwich variance estimator that accounts for the the uncertainty in estimating the parametric nuisance models. Of note, these additional sources of uncertainty
were considered important for accurate variance estimation when parametric models are used to estimate the nuisance parameters in observational studies (Lunceford and Davidian, 2004; Buchanan et al.,
2018; Li and Li, 2019; Mao et al., 2019), and we extend such considerations to these generalizability estimators. In the following, we assume the random vectors, (Di , Di Si , Di Zi , Di Si Xi , Di Si Yi ),
i = 1, . . . , N are IID draws from the target population. Our asymptotic analysis requires the target
population size N to approach infinity, and as N → ∞, the inclusion probability approaches a positive
constant: Π0 = m/(N −n) → π0 . Similar assumptions are used in the choice-based sampling literature
(Scott and Wild, 1986; Li and Allen, 2020)

4.1

e DR2
Large-Sample Distribution of ∆

We first consider the case where only the sampling score and the outcome models are estimated, and the
true propensity score is used. As the sampling scores are estimated by weighted maximum likelihood,
γ
b solves the p × 1 estimating equation
N
X
i=1

N
X
Di Π−1
Si (Si − wi ) ∂
ψγ (Di , Si , Zi ; γ) =
wi = 0,
wi (1 − wi ) ∂γ
i=1

which is obtained from differentiating the weighted binomial log-likelihood of the sampling score model
with respect to γ. The estimation of parameters, α
e1 and α
e0 in the outcome model are based on solving
equations (3.3) and (3.4), with the use of the true propensity scores. We denote the probability limits
of these parameter estimates (b
γ, α
e1 and α
e0 ) as γ ∗ , α1∗ and α0∗ . We use the star superscripts because the
respective models may be misspecified, and thus γ ∗ , α1∗ and α0∗ are probability limits of the potentially
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misspecified models, which are allowed to be different from the parameter values in their respective true
models (White, 1982).
e DR2 = νe1 − νe2 + νe3 , where νe1 , νe2 , νe3 correspond to the three sumIn Web Appendix 3.5, we write ∆
mands in (3.11) but with êi omitted and m
b 1i , m
b 0i replaced by m
e 1i , m
e 0i . Let θe = (e
ν1 , νe2 , νe3 , γ
bT , α
e1T , α
e0T )T ,
e Then θe is the solution for θ∗ in
and define θ∗ = (ν1 , ν2 , ν3 , γ ∗T , α1∗T , α0∗T )T as the limiting value of θ.
P
e
the (3 + p + l1 + l0 ) × 1 estimating equation N
i=1 Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; θ) = 0, where


Di Si Xi (Yi − m1i − ν1 )/(wi ei )




D S (1 − X )(Y − m − ν )/(w (1 − e ))
i
i
0i
2
i
i 
 i i






ci m1i − ci m0i − ν3

.
Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; θ) = 
(4.1)



ψ
(S
,
Z
;
γ)
γ
i
i






Di Si Xi ψα1 (Yi , Zi ; α1 )/ei




Di Si (1 − Xi )ψα0 (Yi , Zi ; α0 )/(1 − ei )
Define A(θ∗ ) = E



∂
∂θT

Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; θ∗ ) and B(θ∗ ) = V {Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; θ∗ )},

where the expectation and covariance operators are defined with respect to the target population. The fact
that the joint estimating equations are unbiased, i.e., E[Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; θ∗ )] = 0, indicates that
under suitable regularity conditions, as N → ∞, N 1/2 (θe − θ∗ ) converges in distribution to N (0, Ωθ∗ ),
where Ωθ∗ = A(θ∗ )−1 B(θ∗ )A(θ∗ )−T (Stefanski and Boos, 2002). By an application of Slutsky’s
e DR2 is a consistent estimator of ∆ and N 1/2 (∆
e DR2 − ∆) converges in
theorem and the delta method, ∆
2 ) where σ 2
T
T
distribution to N (0, σDR2
DR2 = λ Ωθ∗ λ and λ = (1, −1, 1, 01×p , 01×l1 , 01×l0 ) , 0r×c is a

e DR2 is then given by
r × c matrix of zeros. A consistent sandwich variance estimator for ∆
e −1 B(θ)A(
e θ)
e −T λ.
b ∆
e DR2 ) = 1 λT A(θ)
V(
N
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(4.2)

4.2

b DR2
Large-Sample Distribution of ∆

With an estimated treatment propensity score ebi = e(Wi ; β̂), we can write the estimator βb as the solution
to the q × 1 estimating equation
N
X

ψβ (Di , Si , Xi , Wi ; β) =

i=1

N
X
Di Si (Xi − ei ) ∂ei
i=1

ei (1 − ei )

∂β

= 0,

which is obtained from differentiating the binomial log-likelihood of the treatment propensity score
b DR2 = νb1 − νb2 + νb3 , where νb1 , νb2 , νb3
model with respect to β. In Web Appendix 3.5, we write ∆
correspond to the three summands in (3.11), respectively. Let $
b = (b
ν1 , νb2 , νb3 , γ
bT , α
b1T , α
b0T , βbT )T , and
define $∗ = (θ∗T , β T )T as the limiting value of $.
b Then $
b is the solution to the (3+p+l1 +l0 +q)×1
PN
b = 0, where
estimating equation i=1 Φ∆DR2 (Yi , Di , Si , Xi , Zi ; $)


Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; $)
,
Φ∆DR2 (Yi , Di , Si , Xi , Zi ; $) = 
ψβ (Di , Si , Xi , Wi ; β)
where Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; $) = Ψ∆DR2 (Yi , Di , Si , Xi , Zi ; θ) whenever β is chosen such that

e(Wi , β) = ei , the true propensity score. Define C($∗ ) = E ∂$∂ T Φ∆DR2 (Yi , Di , Si , Xi , Zi ; $∗ ) ,
D($∗ ) = V {Φ∆DR2 (Yi , Di , Si , Xi , Zi ; $∗ )}. Notice that E[Φ∆DR2 (Yi , Di , Si , Xi , Zi ; $∗ )] = 0, which
indicates that under suitable regularity conditions, as N → ∞, N 1/2 ($
b − $∗ ) converges in distribution
b DR2 is a consistent
to N (0, Ω$∗ ), where Ω$∗ = C($∗ )−1 D($∗ )C($∗ )−T . Further, we must have ∆
b DR2 − ∆) converges in distribution to N (0, τ 2 ) where τ 2 = η T Ω$∗ η
estimator of ∆ and N 1/2 (∆
DR2
DR2
and η = (λT , 01×q )T . A consistent sandwich variance estimator for ∆DR2 is therefore
b ∆
b DR2 ) = 1 η T C($)
b −1 D($)C(
b
$)
b −T η.
V(
N

4.3

(4.3)

Analytical Comparison

2
2
An analytical comparison between σDR2
and τDR2
reveals that the asymptotic variance is guaranteed to

be no larger when the treatment propensity score is estimated, because
−1
2
2
2
τDR2
= σDR2
− {λT A(θ∗ )GT }Eββ
{λT A(θ∗ )GT }T ≤ σDR2
,
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(4.4)

where G is the lower left off-diagonal block of B(θ∗ ) (defined in Web Appendix 3) and Eββ =
E[Di Si {∂ei /∂β}{∂ei /∂β}T /(ei (1 − ei ))] is a positive definite Hessian matrix. The efficiency gain due
to estimating known propensity scores is a classic result for the inverse probability weighting estimator
in observational studies (Robins et al., 1992; Hirano et al., 2003; Wooldridge, 2007), and (4.4) extends
the same result to doubly robust generalizability estimators. We can also repeat the above derivation for
the rest of the four generalizability estimators, and show that inequality (4.4) still holds true, without
requiring the sampling score or outcomes models to be correctly specified. Proposition 1 below summarizes this comparative finding, with technical details given in Web Appendix 3. Although we show
these inequality results by directly deriving and comparing the asymptotic variances, we remark that
an alternative proof can proceed by treating ei as the sole nuisance parameter and verifying the tangent
space condition in Theorem 3 of Hitomi et al. (2008) for each estimator.
P ROPOSITION 1 Suppose the propensity score is modeled by a smooth parametric model e(W ; β), and
b IPSW1 , ∆
b IPSW2 ,
the parameters are estimated by maximum likelihood. The asymptotic variances of ∆
b REG , ∆
b DR1 , ∆
b DR2 do not exceed those of ∆
e IPSW1 , ∆
e IPSW2 , ∆
e REG , ∆
e DR1 , ∆
e DR2 , respectively.
∆
Interestingly, there exists a stronger version of Proposition 1 stating that including additional baseline covariates in the propensity score model will not compromise the asymptotic efficiency of the generalizability estimator. This result is summarized in Proposition 2, and the proof is provided in Web
Appendix 4.
P ROPOSITION 2 Suppose W1 and W2 are two sets of baseline covariates, and W1 ⊆ W2 , and let
e(W1 ; β1 ) and e(W2 ; β2 ) be smooth nested parametric models in the sense that there exists ξ(β1 )
such that e(W1 ; β1 ) = e(W2 ; β1 , ξ(β1 )) for every β1 , W1 , W2 . If βb1 , βb2 are estimated by maximum
likelihood, and e(W1 ; βb1 ), e(W2 ; βb2 ) are the corresponding estimated propensity scores, then the five
generalizability estimators constructed with e(W2 ; βb2 ) are asymptotically at least as efficient as their
counterparts constructed with e(W1 ; βb1 ).
Proposition 2 grants the use of a more saturated treatment propensity score model with extra covari-
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ates because this strategy does not reduce the large-sample variance of the generalizability estimators.
The insight is that estimating a more saturated propensity scores serves as an implicit step to adjust for
more baseline covariates in trials. Although it has been shown that adjusting additional prognostic covariates improves the efficiency of the SATE estimator (Moore et al., 2011; Shen et al., 2014; Williamson
et al., 2014; Zeng et al., 2020), the role of such adjustment for purpose of generalizability has not been
fully articulated analytically in the generalizability literature such as those in Table 1. Proposition 2
bridges this gap by concluding that improved efficiency in estimating the SATE through implicit covariate adjustment, can translate into potentially improved efficiency in estimating the PATE, across all five
generalizability estimators.

5
5.1

Assessing Generalizability of ACTG 320 and ACTG A5202
Trial and Cohort Data

The ACTG 320 trial enrolled participants between January 1996 and January 1997 and examined the
efficacy of adding a PI to an HIV treatment regimen with two nucleoside analogues (Hammer et al.,
1997). Around 20% of the 1,156 participants were women. We focus on the change in the CD4 cell
counts as the outcome of interest, and a treatment regimen is favored if it leads to an increase in CD4 cell
count from baseline (i.e., reflects improvements in immunological functioning). At week 4 follow-up,
116 (10%) patients had missing CD4 cell count and were excluded from this analysis. The baseline
characteristics of the excluded patients were not systematically different from the remaining patients,
and therefore we only considered a complete-case analysis to focus on the generalizability aspect of the
problem. The ACTG A5202 trial enrolled participants between September 2005 and November 2007
and assessed the equivalence of ABC-3TC or TDF-FTC plus efavirenz or ritonavir-boosted atazanavir
(Sax et al., 2009, 2011). About 17% of the 1,857 participants were women. At week 48 follow-up, 417
(22%) patients had missing CD4 cell count and were likewise excluded. Web Tables 1 to 4 summarize
the baseline characteristics of all participants and the women subgroup by study arms. In both trials,
the majority of participants are between 30 to 40 years old. While the majority (53% and 41%) of all
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participants in ACTG 320 and ACTG 5202 were non-Hispanic White, the majority (46% and 55%) of
all women participants in ACTG 320 and ACTG 5202 were African-American.
For this analysis, we assume the CNICS and WIHS cohorts to be representative samples from their
respective target populations, namely, all people living with HIV in the USA, and all women living
with HIV in the USA. With comprehensive clinical data from point-of-care electronic medical record
systems for population-based HIV research, the CNICS cohort includes over 27,000 HIV-infected adults
from eight USA CFAR sites (Kitahata et al., 2008). On the other hand, the WIHS cohort includes 4,129
women recruited from six USA sites, and represents the oldest prospective cohort study of women with
and at risk for HIV infection (Bacon et al., 2005; Adimora et al., 2018). We respectively harmonize
the two cohorts so that the final cohort samples each match the key eligibility criteria in the two ACTG
trials. In particular, we selected the first record for a participant in the cohort study that met key study
inclusion criteria specific to each trial. For generalizing ACTG 320, we restrict the cohort sample to
those who were HIV-positive, highly active antiretroviral therapy (HAART) naive, and had CD4 cell
counts lower than 200 cells/mm3 at the previous visit. This leads to m = 6, 158 participants from
CNICS and m = 493 women from WHIS. For generalizing ACTG A5202, we restrict the cohort sample
to those who were HIV-positive, antiretroviral therapy (ART) naive, and had viral load greater than 1000
copies/ml at the previous visit. This provides m = 12, 302 participants from CNICS and m = 1, 012
women from WIHS. Baseline characteristics of the resulting cohort samples, including calendar time of
visit, time since ART initiation, age, CD4 cell count, and viral load, are summarized in Web Tables 5
and 6. Finally, based on the Centers for Disease Control and Prevention (2012) estimates, the size of the
first target population is assumed to be N = 1.1 million (all people living with HIV), and the size of the
second target population is assumed to N = 280, 000 (women living with HIV).

5.2

Model Specifications and Balance Check

For each analysis, the combined ACTG trial and cohort sample is used to fit a weighted logistic model
and estimate the sampling scores. The sampling score model includes variables associated with selection
into the trial or treatment effect modifiers with a linear term for continuous variables, as well as all
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pairwise interactions. Sex, race, age, history of injection drug use (IDU), and baseline CD4 are included
in the sampling score model for generalizing ACTG 320, while sex, race, age, history of IDU, hepatitis B
or C, AIDS diagnosis, baseline CD4 and baseline viral load (on log10 scale) are included in the sampling
score model for generalizing ACTG A5202. We also incorporated a squared age term and its interactions
with other covariates because this strategy improves weighted covariate balance. Sex is excluded in the
sampling score model when generalizing the trial results among the women subgroup.
Figure 1 presents the histograms of estimated sampling scores. The histograms facilitate a visual
check on the positivity assumption for trial participation. Even though the magnitude of the sampling
scores is generally small due to the large population size N , the distribution of sampling scores between
the trial and cohort do not signal a strong lack of common support (also see Web Figure 1 for a zoomed
version of the tails for each histogram). To further check the adequacy of the estimated sampling scores,
we calculate the balance for each covariate between the weighted sample and population. Extending the
definition of Austin and Stuart (2015), we define the standardized mean difference (SMD) for non-nested
design as
1
SMD =
s

PN

i=1 Di Si Zi(k) πi
PN
i=1 Di Si πi

PN
−

i=1 Di {Si

+ Π−1
0 (1 − Si )}Zi(k)
,
N

where Zi(k) is the kth regressor included in the sampling score model. The denominator s is the standard
deviation of Zi(k) in the target population and estimated by
(
)
P
−1
2 1/2
mN N
i=1 Di {Si + Π0 (1 − Si )}(Zi(k) − Z̄(k) )
s=
,
m(N 2 − n) − (N − n)2
where Z̄(k) =

PN

i=1 Di {Si

+ Π−1
0 (1 − Si )}Zi(k) /N is the population average. This expression is es-

sentially the weighted standard deviation of each covariate with weights Π−1
Si . When πi = 1, SMD
quantifies the systematic difference between the trial and population, and reflects the degree of trial
sample selection bias. When πi = w
bi−1 , the SMD measures the similarity between the weighted trial
and population, and is used as a diagnostic check of the sampling score weights. Figure 2 summarizes
the SMD of all covariates before and after sampling score weighting across the four analyses. In Web
Figures 2 to 5, we also provide the forest plot of the SMD by each covariate for each generalizability
analysis. It is evident that the sampling score weights improve balance between trial and population,
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with the largest SMD controlled under 20% after weighting (an exception is when generalizing A5202
to WHIS, where the SMD for baseline CD4 and one interaction term with baseline CD4 are slightly
above 20%). While a more stringent balance threshold (10%) has been previously suggested for analyzing observational studies (Austin and Stuart, 2015), here we use 20% as a less stringent threshold due to
the large pre-existing differences in the trial and population sizes.
[Figure 1 about here.]
[Figure 2 about here.]
We retain the same set of covariates in the outcome model as in the sampling score model. Linear
regression including main effects and all pairwise interactions were fit among the trial participants. We
follow the strategy in Section 3.3 and fit separate outcome models within each treatment group, before
predicting the unobserved potential outcomes for the entire observed sample. In particular, among
women in ACTG A5202, there are no participants in the control group with both hepatitis B/C and an
AIDS diagnosis, so this interaction term is excluded. The quantile-quantile plots of regression residuals
do not suggest violations of the normality assumption and are omitted for brevity.
We consider both the true propensity scores (ei = 0.5) and the estimated propensity scores (b
ei ) in
constructing the estimators for PATE. To estimate the treatment propensity scores, we specify a logistic regression of treatment on a set of baseline covariates Wi . Two strategies are used to specify Wi .
The first strategy only includes the main effects of baseline covariates and represents a more parsimonious specification (referred to as main-effects logistic model). Information of baseline covariates by
treatment group in the trials are summarized in Web Tables 1 to 4. The second strategy includes the
main effects and pairwise interactions of all baseline covariates in Wi (referred to as full logistic model).
Due to sparse cell counts, we include race as binary variable (White vs. non-White) in the propensity
score model when generalizing ACTG A5202 to all women living with HIV in the USA (WIHS cohort).
In this particular analysis, the following pairwise interactions are also excluded from the full logistic
propensity score model to avoid numerical issues with sparse cell counts: race-hepatitis, race-AIDS,
race-IDU, squared-age-IDU, hepatitis-AIDS, and IDU-AIDS. Compared to the analyses using the true
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treatment propensity scores, Proposition 1 indicates that the above two strategies of specifying Wi can
control for important baseline covariates and improve the precision of the PATE estimators. Furthermore, Proposition 2 suggests there is no asymptotic efficiency loss by over-specifying the propensity
score model, as in the second strategy. For each analysis, we estimate the variance and associated 95%
confidence interval for PATE using the proposed sandwich variance estimator. The study protocol was
reviewed and approved by the University of Rhode Island Institutional Review Board.

5.3

Assessing Generalizability

The SATE in each trial is estimated by the difference-in-means estimator (Table 2). In ACTG 320, there
is a notable improvement in the CD4 cell response from baseline to 4 weeks among patients included
in the PI group compared to those in the non-PI group, both overall (SATE = 19) and for the women
subgroup (SATE=24). These changes are statistically significant at the 5% level as the 95% confidence
intervals (CIs) are (12, 25) and (7, 41), respectively. In ACTG A5202, those randomized to ABC-3TC
had slightly higher average change in CD4 cell count from baseline to week 48 compared to those
randomized to TDF-FTC (SATE=6). Among the women subgroup, the two treatment groups had a
similar average change in CD4 (SATE=1). The results in ACTG A5202 are not statistical significant at
the 5% level as the respective 95% CIs are (−8, 20) and (−35, 37).
[Table 2 about here.]
Table 2 summarizes the PATE estimates in both target populations generalized from each ACTG
trial. The analysis is conducted using both the true propensity score and the estimated propensity scores;
all CIs are based on the sandwich variance estimators developed in Section 4 and Web Appendix 3. We
also present the results in Figure 3, facilitating a graphical comparison across the three sets of results
obtained with different treatment propensity score estimates. First, the three sets of results in Table 2 and
Figure 3 empirically illustrates the asymptotic findings in Proposition 1 and 2 in that the CIs obtained
with the main-effects logistic propensity score model are generally no wider than those obtained with
the true propensity score, and the CIs obtained with the full logistic propensity score model are often
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the narrowest. The differences in widths of CI can be substantial for each of the five estimators, with
the largest differences observed when generalizing ACTG A5202 to all women living with HIV. In the
following, we mainly interpret the results with the full logistic propensity score model as they appear to
be the most efficient.
[Figure 3 about here.]
For generalizing the ACTG 320 to the target population of all people living with HIV, the PATE estimate is generally similar to the SATE estimate, regardless of the use of IPSW, REG or DR approaches;
b IPSW2 = 18, ∆
b REG = 14 and ∆
b DR2 = 15. The generalization analfor example, PATE is estimated as ∆
ysis slightly inflates variance and leads to wider CIs. Specifically, the 95% CIs of PATE are (10, 25),
(5, 23) and (6, 24) using the IPSW2, REG and DR2 methods, suggesting that the combination with PI
is likely to induce positive CD4 response in the target population with a comparable magnitude as in
ACTG 320. For generalizing ACTG A5202 to the target population of all people living with HIV in the
USA, while the SATE estimate is positive, the PATE estimates are mostly negative. The 95% CIs for
PATE are fairly symmetric around the null; for example, the 95% CIs of PATE are (−24, 22), (−27, 23)
and (−29, 22) using the IPSW2, REG and DR2 methods. Overall, the effect of PI in ACTG 320 may
be more generalizable to the target population of all people living with HIV in the USA, whereas the
effect the ART combination ABC-3TC (versus TDF-FTC) may be less generalizable to this same target
population.
In the target population of all women living with HIV in the USA, the PATE estimates obtained by
b IPSW1 = 38, ∆
b IPSW2 = 39
IPSW are approximately 1.6 times the SATE estimate from ACTG 320 (∆
b REG = 25), and the two DR
compared to SATE= 24). The REG estimate appears closer to SATE (∆
estimates fall in between IPSW and REG estimates. Using the full logistic propensity score model,
while the two CI estimates from IPSW exclude zero (95% CI is (16, 60) from IPSW1 and (17, 61)
from IPSW2), the CI estimates from REG and DR contain zero (95% CI is (−6, 55) from REG and
(−3, 60) from DR1 and DR2). On the other hand, all PATE CIs exclude zero when using the maineffects logistic propensity score model; for example, the 95% CI of PATE is (3, 68) from REG and
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(6, 74) from DR1 and DR2. The magnitudes of the PATE estimates using either propensity score model
specification suggest that the within-trial SATE estimate may slightly underestimate the treatment effect
of PI for all HIV-infected women in the USA. When generalizing ACTG A5202 to the target population
of all women living with HIV, the PATE estimates using IPSW suggest a much greater CD4 cell count
increase from baseline compared to the SATE estimate. While IPSW1 provides the largest point estimate
b IPSW1 = 52) with a much wider CI (−39, 144), the PATE estimates obtained with other approaches
(∆
are smaller and had narrower CIs; the 95% CIs for PATE are (−28, 75) under IPSW2, (−75, 57) under
REG, (−75, 58) under DR1 and (−75, 59) under DR2. Among them, the IPSW2 estimate still indicates
b IPSW2 = 24), but this
a protective effect of ABC-3TC (versus TDF-FTC) in the target population (∆
estimated effect is attenuated and becomes negative when using REG and DR with the full logistic
propensity score model. Likewise, the PATE estimates are attenuated by both REG and DR when using
the main-effects logistic propensity score model, though they remain positive. In this analysis, because
the DR estimates are closer to REG than to IPSW, the results signify a potentially misspecified sampling
score model. However, the estimated 95% CI for PATE from each method contains zero, and therefore
the PATE is not significantly different from null at the 5% level. The differences between the SATE and
PATE estimates imply that results from ACTG A5202 may not be directly generalizable to all women
living with HIV.
Finally, even though we consider the Centers for Disease Control and Prevention (2012) estimates
as the best guesses for the target population size N , we also carried out additional analyses to assess the sensitivity of the PATE estimates to different assumptions of N . In particular, we specify
N ∈ {0.7 million, 1.5 million} when the target population is all people living with HIV and with
N ∈ {230000, 330000} when the target population is all women living with HIV. The former represents
a scenario where the population size estimate is off by 0.4 million and the latter where the population
size estimate is off by 50000, in either direction. The point and interval estimates for PATE are presented in Web Tables 7 and 8. For this application, we observe that the PATE estimates obtained by each
method were generally insensitive to the specified larger and smaller sizes of the target populations.
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6

Simulation Studies

6.1

Main Simulation Design

We conduct a simulation study that mimics the motivating setting to further elucidate the comparison
between IPSW, REG and DR estimators in scenarios with two effect modifiers and a continuous outcome. We generate one binary covariate Zi1 ∼ Bernoulli(0.4) and one continuous covariate Zi2 from
N (0, 1). We assume a target population of size N = 1 million, where the true sampling score is
wi = {1 + exp(−γ0 − γ1 Z1i − γ2 Zi2 − γ3 Zi1 Zi2 )}−1 . A Bernoulli trial participation indicator, Si , is
generated based on wi and only those with Si = 1 participate in the trial. Among the trial participants,
the treatment indicator is randomized with Xi ∼ Bernoulli(0.5); the potential outcomes are generated
from
Yi1 =α10 + α11 Z1i + α12 Zi2 + α13 Zi1 Zi2 + 1i ,
Yi0 =α00 + α01 Z1i + α02 Zi2 + α03 Zi1 Zi2 + 0i ,
where 1i , 0i are independent N (0, 1) error terms. We choose α10 = 2, α01 = α02 = α03 = −1 and
α00 = 0, and vary the values of α11 , α12 , α13 to represent different levels of effect modification. Define
ζ1 = α11 − α01 , ζ2 = α12 − α02 , ζ3 = α13 − α03 and Zi1 , Zi2 , Zi1 Zi2 will be considered as effect
modifiers as long as the association parameters ζ = (ζ1 , ζ2 , ζ3 )T are nonzero. The sampling score model
parameters γ = (γ0 , γ1 , γ2 , γ3 )T are chosen such that the trial size is n ≈ 1, 000. We also simulate a
cohort as a random sample of size m = 4, 000 from the target population (less those selected into the
trial). Similar to the motivating application, the number of participants in the trial is small compared
to the size of the target, and the cohort can be considered as a simple random sample from the target
population. Furthermore, this choice of sample sizes resembles those for generalizing the two ACTG
trials to the population represented by the CNICS cohort.
We consider four scenarios with two sets of different values of γ and two sets of values of ζ. We
choose γ = (−7.148, 0.3, 0.3, 0.3)T and γ = (−7.698, 0.6, 0.6, 0.6)T to represent moderate and strong
selection effect in trial participation, and set ζ = (1, 1, 1)T , ζ = (2, 2, 2)T to denote moderate and
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strong effect modification. We calculate the true PATE for each scenario based on the distribution of
Zi1 , Zi2 in the target population, and obtain ∆ = 2.4 and ∆ = 2.8 with moderate and strong effect
modification. To estimate the sampling score, the combined trial and cohort sample is used to fit a
weighted logistic model with Si as the outcome variable. To predict the potential outcomes in the
combined trial and cohort data, linear models are fit among the trial sample. We simulate 5,000 data
replications for each scenario and evaluate the performance of the two IPSW, REG and the two DR
estimators. Both correct and incorrect model specifications are studied whenever applicable. In this
simulation, a misspecified sampling score model does not include the interaction term Zi1 Zi2 , whereas
an incorrect outcome model likewise omits Zi1 Zi2 . For each estimator, we consider the version that
used the true treatment propensity score versus the version that used the estimated propensity score
with Zi1 and Zi2 . Such comparisons could illustrate the potential efficiency gain due to estimating the
known propensity scores in the generalizability setting. Finally, the following quantities are computed
for each scenario: the bias to ∆, empirical standard error (ESE), average of the estimated standard errors
(ASE), and empirical coverage probability of the 95% CIs constructed from the standard errors based
on the proposed sandwich variance estimators. In addition to the main simulations, we also conduct
additional simulations to assess the impact of misspecifying the target population size N as well as a
smaller trial sample size and/or cohort sample size. Those results are reported in Section 6.3. The R
code for implementing the simulation studies can be found in Web Appendix 5.

6.2

Main Simulation Results

We report the simulation results with moderate selection effect and moderate effect modification in Table
3; results for the remaining three scenarios generally have similar patterns and are found in Web Tables
9 to 11. When the sampling score model is correctly specified, both IPSW1 and IPSW2 are unbiased
and the associated 95% CIs have close to nominal coverage with the use of proposed sandwich variance
estimators. We also observe that using the estimated propensity scores could substantially reduce the
variability of IPSW. Interestingly, although IPSW2 is more efficient than that IPSW1 in most scenarios,
the former becomes less efficient than the latter when the both selection effect and effect modification
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become strong (Web Table 11). When the sampling score model is misspecified, IPSW is biased, even
though the average sandwich standard error estimates stay close to the empirical standard errors; the bias
of IPSW2 is larger than the bias of IPSW1 when the interaction term is omitted from the sampling score
model. When the outcome models are correctly specified, the REG estimator is consistent and more
efficient than IPSW. As expected, when the outcome models are misspecified, the REG estimator has
nontrivial bias. Weighting the outcome models by an estimated propensity scores has minimum effect
on the efficiency of the REG estimator across all scenarios, which is concordant with the discussion in
Section 4.3 that exploiting an estimated propensity score does not increase the asymptotic variance.
[Table 3 about here.]
The simulation results also demonstrate the robustness properties of the DR1 and DR2 estimators;
that is, both estimators have negligible bias when either the sampling score model or the outcome models
are correct, but not necessarily both. To further illustrate the double robustness and asymptotic normalb DR2 (over 5000 simulations) under correct and incorrect
ity, we present the empirical histograms of ∆
model specifications in Web Figure 6. Furthermore, when all models are correctly specified, DR1 and
DR2 are substantially more efficient than IPSW1 and IPSW2. For instance, when the true treatment
e DR1 to ∆
e IPSW1 ranges from 1.46 to 1.94 while the
propensity scores are used, the relative efficiency of ∆
e DR2 to ∆
e IPSW2 ranges from 1.33 to 2.02. When the propensity scores are estirelative efficiency of ∆
b DR1 to ∆
b IPSW1 ranges from 1.20 to 1.69 while the
mated from the trial sample, the relative efficiency of ∆
b DR2 to ∆
b IPSW2 ranges from 1.21 to 2.03. Despite the efficiency gain over IPSW
relative efficiency of ∆
estimator, the DR estimators remain close but no more efficient than REG. Frequently, misspecification
of the outcome models leads to more variable DR estimates than misspecification of the sampling score
model, a phenomenon that is consistent with previous investigations in observational studies (Li et al.,
2013). The average of the DR sandwich standard error estimates is generally close to the empirical standard error across all scenarios, indicating the adequacy of the proposed sandwich variance estimators.
When all models are misspecified, DR1 and DR2 are biased for the true PATE.
Overall, DR1 and DR2 perform similarly across scenarios except when the outcome models are
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correctly specified but the sampling score model is not. In that case, DR2 shows higher efficiency over
DR1, especially under strong selection effect for trial participation. For this reason, our simulation
results favor DR2 over DR1. Correspondingly, using an estimated treatment propensity score generally
has minimum effect on efficiency for both DR estimators, except when the sampling score model is
correctly specified and the outcome models are not. In that case, estimating the known propensity score
slightly improves the efficiency for both DR estimators under moderate effect modification in Table 3.
Therefore, it may still be appealing to consider an estimated propensity score as it does not appear to
adversely affect the finite-sample efficiency of DR estimators in the settings we considered.

6.3

Additional Simulations

Our main simulation studies assume the target population size is known to be N = 1 million, and
relatively large compared to the trial and cohort sample sizes to mimic the two ACTG trials and the
CNICS cohort. To generate additional empirical evidence, we conduct further assessments to investigate (1) the impact of misspecification of the target population size N , and (2) the performance of the
generalizability estimators with a smaller trial sample size, n, and/or cohort sample size, m. We consider the most challenging scenario with a strong selection effect and strong effect modification with
γ = (−7.698, 0.6, 0.6, 0.6)T and ζ = (2, 2, 2)T . We only present the estimators with estimated propensity scores, as the results for the estimators with true propensity scores are completely analogous. Web
Table 12 summarizes the performance of all five generalizability estimators when the target population
size N is underestimated to 0.8 million and 0.5 million (without altering the data generation process in
Section 6.1). Interestingly, the results for all five estimators are almost identical to those when the target
population size is correctly specified. Similarly, the performance of all five estimators is also nearly
unaffected when the target population size is overestimated to be 1.2 million and 1.5 million (Web Table
13). A likely explanation is that the true target population size N is large enough such that there is a
relatively large indifference range of N within which the PATE estimates are relatively stable. This finding also matches our sensitivity analyses in Section 5 with slightly larger and smaller N , under which
the PATE point and interval estimates remain nearly unchanged. Lastly, in the case when the target
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population size N is severely underestimated to be 0.1 million and 0.05 million, Web Table 14 indicates
that the bias of all estimators becomes nontrivial, with under-coverage especially in the latter scenario.
However, with a correctly specified sampling score model even when N = 0.1 million, the coverage of
DR1 and DR2 estimators remains nominal, and when N = 0.05 million, both doubly-robust estimators
have coverage over 90% while both IPSW1 and IPSW2 can often exhibit notable under-coverage.
To investigate the performance of all five generalizability estimators with smaller (observed) sample
sizes, we repeat the simulation study with (n, m) ∈ {(200, 4000), (1000, 800), (200, 800)}, representing scenarios with a smaller trial sample size only, a smaller cohort sample size only, and smaller trial
and cohort sample sizes. While the result patterns in Web Tables 15 and 16 are generally consistent
with our main simulation with (n, m) = (1000, 4000), we observe that IPSW can exhibit excessive
variance and under-coverage when the trial sample size decreases from 1000 to 200. In addition, IPSW2
appears to be less stable compared to IPSW1 when the trial sample size is small, demonstrating larger
bias and lower coverage. In contrast, the performance of REG, DR1 and DR2 estimators are more stable
when either the trial or the cohort sample size decreases. Even in the smallest sample size scenario with
(n, m) = (200, 800), the DR estimators maintain nominal coverage when at least one model is correctly
specified. Finally, while the accuracy of generalizability estimators is affected by both the trial sample
size and the cohort sample size, the trial sample size appears to play a dominating role. This is expected
because the trial sample contains information on both the effect modifiers and the outcome, whereas the
cohort sample does not contain information on the outcome.

7

Discussion

In this article, we consider generalizing trial results from ACTG 320 and ACTG A5202 to two separate
target populations. Our findings suggest the three-drug therapy with PI may lead to significant increase
in CD4 cell counts among all people living with HIV, just as in ACTG 320. Likewise, the three-drug
therapy with PI may lead to significant increase in CD4 cell counts among all women living with HIV,
but with a potentially larger magnitude compared to women participants in ACTG 320. In contrast, the
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comparative evidence in ACTG A5202 appears less generalizable to the specified target populations.
Unlike the compelling comparative evidence associated with ACTG 320, neither the SATE in ACTG
A5202 nor the associated PATE estimate are significantly different from zero.
Our generalizability estimators require conditional exchangeability between the trial sample and
population given measured covariates. This assumption is not testable without additional information
of the outcome in the target population (Hartman et al., 2015) and could be violated if there exist unmeasured common causes of trial participation and the outcome. In cases where some potential effect
modifiers are measured only in the trial but not in the target population, Nguyen et al. (2017) developed strategies for sensitivity analysis given assumed population-level information on the missing effect
modifiers. It would be valuable for future work to adapt their approaches to our setting.
A second assumption we made is that the CNICS and WIHS cohorts are representative of the two
target populations. Such an assumption is not directly testable with observed data and may be violated if
participation in the cohort studies depends on demographic characteristics, access to health care, as well
as medical history. To further address the difference between the cohort sample and target population,
one needs to weight the cohort sample to approximate the covariate distribution of the target population. In the special case where the cohort study is a well-designed population survey with known survey
weights, Ackerman et al. (2021) developed the IPSW generalizability estimator that properly incorporated the survey weights. Using a similar strategy, it is possible to further extend our DR estimators in
Section 3 by replacing Π−1
0 with the known survey weights to estimate PATE.
While previous studies that estimate the PATE have implemented bootstrap approaches for inference (Dahabreh et al., 2018), we have developed a set of closed-form sandwich variance estimators for
inference. Our variance estimators extend the recent work of Buchanan et al. (2018), and are computationally more efficient than bootstrapping. Additionally, the development of the sandwich variance
also has practical implications for our application because the we found certain interaction parameters
in the outcome model are frequently not estimable during a bootstrapping procedure. For example, due
to small trial sample size and sparse cell counts, there is no information to estimate the interaction between race and IDU, as well as IDU and baseline CD4 among 471 out of 1000 bootstrap replicates,
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when we generalize ACTG A5202 to all women living with HIV. This may raise concerns as one would
have to change model specification for purpose of inference. The proposed sandwich variance estimator, to some extent, circumvents this issue, but still takes into account the uncertainty in estimating the
parametric sampling scores, outcome models and/or propensity score model. In our simulations with
comparable population sizes to the motivating application, the sandwich variance estimates are close to
the empirical variances even under model misspecification. We provide R code for implementing the
sandwich variance estimators in Web Appendix 5.
For estimating PATE, we formally demonstrated that generalizability estimators constructed with
an estimated propensity score are asymptotically at least as efficient as those constructed with the true
propensity score. In fact, using an estimated propensity score can be regarded as an implicit step to
perform baseline covariate adjustment, which is known to increase the efficiency of within-trial SATE
estimator (Moore et al., 2011; Shen et al., 2014; Williamson et al., 2014; Zeng et al., 2020). Our simulation evidence suggests that using an estimated propensity score leads to more substantial efficiency
gain for IPSW estimators and occasionally DR estimators with a misspecified outcome model. Our application also favors the use of a more saturated logistic model for estimating the propensity score in the
trial, as it leads to substantially narrower CIs for PATE. While this strategy is supported by large-sample
results, there is a tradeoff between asymptotic efficiency and finite-sample stability. In practice, when
the trial is of a limited sample size (say less than 100), using a more saturated logistic model for the
propensity score may result in overfitting, and can even compromise the finite-sample stability of the
PATE estimates.
We acknowledge several limitations of our generalizability analyses which merit further study. First,
we have created the cohort samples (CNICS and WIHS) by applying the ACTG trial inclusion criteria
but without matching the recruitment years. Because the majority of our data is from the post-HAART
era, we prioritized addressing the differences concerning the observed clinical characteristics rather
than the unobserved differences related to calendar year. In other words, we have assumed that the
trials and the harmonized cohorts are sampled from the same underlying target population, even if the
recruitment years do not completely overlap. It would be of interest to ascertain additional data that also
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eliminate the temporal differences between trials and cohorts. Second, we have excluded the participants
in ACTG trials with missing CD4 counts at follow-up. If the outcomes are not missing completely at
random, the difference-in-means estimator of the SATE may be biased, which can lead to a biased IPSW
estimate of PATE, even if the sampling score model is correctly specified. If the outcomes are missing at
random, one could apply our generalizability estimators to multiply-imputed trial data sets and combine
the results using the Rubin’s rule. Finally, we have defined the causal estimand based on the entire
population including the trial participants. An equally relevant estimand is the target average treatment
effect (TATE) among the trial non-participants, defined as TATE = E(Y 1 − Y 0 |S = 0) (Nguyen et al.,
2017). Estimation of TATE requires the use of inverse odds weights (Westreich et al., 2017) instead of
the inverse probability of sampling weights. When the cohort sample is a subset of the target population
(m < N ), it would be interesting to further investigate the necessity or potential benefit of incorporating
the target population size N to the inverse odds weights, similar to the arguments made in Section 3.1.
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Table 1

A synthesis of methods for generalizing trial results to target populations based on the potential

outcomes framework, and classification by techniques for variance estimation, mode of inference and
model assumptions.
Design

Method

Reference

Nested

Subclassification

Stuart et al. (2011) , Tipton (2013)† , O’Muircheartaigh and Hedges (2013)†

Weighting

Stuart et al. (2011) , Dahabreh et al. (2018, 2020)\

Regression

Dahabreh et al. (2018, 2020)\

Doubly robust

Dahabreh et al. (2018, 2020)\ , Li et al. (2021)]

Non-

Subclassification

Buchanan et al. (2018)†

nested

Weighting

Cole and Stuart (2010)† , Hartman et al. (2015)] , Buchanan et al. (2018)‡ , this article‡

Regression

Wang and Rosner (2019)§ , this article‡

Doubly/multiply robust

Rudolph and van der Laan (2017)[ , Lee et al. (2021)] , this article‡

 variance estimation not discussed (frequentist, with parametric models);
\ implemented bootstrap variance (frequentist, with parametric models);
] implemented bootstrap variance (frequentist, calibration weighting);
† implemented (sandwich) variance which ignores the uncertainty in estimating nuisance parameters (frequentist, with
parametric models);
‡ implemented (sandwich) variance which takes into account the uncertainty in estimating nuisance parameters (frequentist,
with parametric models);
§ variance obtained from posterior summaries (Bayesian, with nonparametric priors);
[ variance estimated by sample variance of the efficient influence curve (frequentist, targeted maximum likelihood estimation with ensemble machine learner).
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Figure 1 Histograms of estimated sampling scores for each of the four generalizability analyses.
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(b) Trial (A5202) and cohort (CNICS)
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PATE estimates and 95% confidence intervals. The three sets of results correspond to general-

izability estimators that use (i) the true propensity score (PS method=True); (ii) the estimated propensity
score using a main-effects logistic model (PS method=Main); and (iii) the estimated propensity score
using a full logistic model (PS method=Full). The dashed lines indicate results for the within-trial
SATE.
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Table 2 Estimated within-trial sample average treatment effect (SATE) and target population average treatment effects
(PATE) on change in CD4 cell counta and corresponding 95% confidence intervals based on proposed sandwich variance
estimators. Trial data are from ACTG 320b and ACTG A5202c ; the WIHS and CNICS cohorts are used to create random
samples from two target populations (all people N = 1.1 million and all women living with HIV in the USA N = 280, 000).
The three sets of results correspond to generalizability estimators that use (i) the true propensity score among trial participants
ei = 1/2; (ii) the estimated propensity score using a logistic regression model with main effects for all covariates and a
quadratic term for age; and (iii) the estimated propensity score using a more complex logistic regression model with main
effects for all covariates, a quadratic term for age, and all pairwise interactions between covariates.
SATE
m

Cohort

Trial

n

PATE

PATE

PATE

PATE

PATE

IPSW1

IPSW2

REG

DR1

DR2

True propensity scores
CNICS

6,158

320

1,040

19 (12, 25)

20 (11, 29)

18 (10, 26)

14 (5, 23)

15 (6, 24)

15 (7, 24)

CNICS

12,302

A5202

1,440

6 (-8, 20)

5 (-27, 36)

1 (-26, 28)

-2 (-27, 24)

-3 (-29, 24)

-3 (-29, 24)

WIHS

493

320

173

24 (7,41)

52 (19, 86)

42 (15, 69)

32 (-2, 65)

37 (1, 73)

37 (2, 72)

WIHS

1,012

A5202

255

1 (-35, 37)

106 (-44, 256)

31 (-44, 105)

0.04 (-103, 104)

4 (-84, 92)

4 (-85, 92)

Estimated propensity scores with main-effects logistic model
CNICS

6,158

320

1,040

19 (12, 25)

18 (10, 26)

17 (9, 25)

14 (5, 23)

15 (7, 24)

15 (7, 24)

CNICS

12,302

A5202

1,440

6 (-8, 20)

-2 (-26, 31)

0.33 (-24, 25)

-1 (-27, 25)

-1 (-27, 25)

-1 (-27, 25)

WIHS

493

320

173

24 (7,41)

41 (13, 69)

47 (21, 73)

35 (3, 68)

40 (6, 74)

40 (6, 74)

WIHS

1,012

A5202

255

1 (-35, 37)

81 (-49, 211)

37 (-37, 111)

10 (-90, 110)

11 (-75, 96)

11 (-75, 96)

Estimated propensity scores with full logistic model
CNICS

6,158

320

1,040

19 (12, 25)

18 (10, 25)

18 (10, 25)

14 (5, 23)

15 (6, 24)

15 (6, 24)

CNICS

12,302

A5202

1,440

6 (-8, 20)

0.24 (-21, 22)

-1 (-24, 22)

-3 (-27, 23)

-4 (-29, 22)

-4 (-29, 22)

WIHS

493

320

173

24 (7,41)

38 (16, 60)

39 (17, 61)

25 (-6, 55)

28 (-3, 60)

28 (-3, 60)

WIHS

1,012

A5202

255

1 (-35, 37)

52 (-39, 144)

24 (-28, 75)

-9 (-75, 57)

-8 (-75, 58)

-8 (-75, 59)

a

For ACTG 320, the outcome is change in CD4 cell count from baseline to week 4. For ACTG A5202, the outcome is

change in CD4 cell count from baseline to week 48.
b

For ACTG 320, the treatment contrast is protease inhibitor (X = 1) versus no protease inhibitor (X = 0).

c

For ACTG A5202, the treatment contrast is abacavir-lamivudine (X = 1) versus tenofovir disoproxil fumarate-

emtricitabine (X = 0) plus efavirenz or ritonavir-boosted atazanavir.
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Table 3

Comparison of performance of five different estimators for estimating PATE with 5000 sim-

ulated data replications with (γ1 , γ2 , γ3 ) = (0.3, 0.3, 0.3) and (α1 , α2 , α3 ) = (1, 1, 1) in the main
simulation. The true PATE ∆ = 2.4. ESE: Empirical standard error; ASE: Average of the estimated
standard errors.
Estimator

Correct w(Zi ; γ)

Correct mx (Zi ; αx )

True treatment propensity scores used
√
e IPSW1
∆

Bias

ESE (×100)

ASE (×100)

Coverage (×100)

–

0.00

12.3

12.9

95.7

e IPSW1
∆
e IPSW2
∆

×
√

–

0.02

12.8

13.5

95.3

–

0.00

10.1

10.1

95.3

e IPSW2
∆
e REG
∆

×

–
√

-0.02

10.2

10.3

94.8

0.00

7.5

8.3

96.9

e REG
∆
e DR1
∆

–
√

×
√

0.03

8.1

8.9

95.9

0.00

7.5

8.4

96.8

×
√

0.00

8.0

8.8

96.9

0.00

7.5

8.4

96.9

×
√

0.09

8.2

9.1

85.3

0.00

7.5

8.4

96.8

×
√

0.00

8.0

8.8

97.0

0.00

7.5

8.4

96.9

×

0.09

8.2

9.0

85.2

Estimated treatment propensity scores used
√
b IPSW1
∆
–

0.00

9.0

9.7

96.7

0.02

9.1

9.8

96.0

e DR1
∆
e DR1
∆
e DR1
∆
e DR2
∆
e DR2
∆
e DR2
∆
e DR2
∆

–

√
×
×
√
√
×
×

b IPSW1
∆
b IPSW2
∆

×
√

–
–

0.00

9.1

9.1

95.1

b IPSW2
∆
b REG
∆

×

–
√

-0.02

9.1

9.1

94.7

0.00

7.5

8.3

96.9

b REG
∆
b DR1
∆

–
√

×
√

0.03

8.0

8.8

95.8

0.00

7.5

8.4

96.7

×
√

0.00

7.9

8.8

96.9

0.00

7.5

8.4

96.9

×
√

0.09

8.2

9.0

85.4

0.00

7.5

8.4

96.7

×
√

0.00

7.9

8.8

97.0

0.00

7.5

8.4

96.9

×

0.09

8.2

9.0

85.4

b DR1
∆
b DR1
∆
b DR1
∆
b DR2
∆
b DR2
∆
b DR2
∆
b DR2
∆

–

√
×
×
√
√
×
×
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